Aprea Therapeutics Reports Promising Early Results from ACESOT-1051 Trial for WEE1 Kinase Inhibitor APR-1051
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2025
0mins
Source: Newsfilter
Clinical Trial Results: In the ongoing Phase 1 ACESOT-1051 trial, 3 out of 4 patients treated with a 100 mg dose of APR-1051 achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies, with disease stabilization linked to specific genetic mutations.
Dose Escalation: Following the positive results at the 100 mg level, the trial has progressed to a 150 mg cohort, with no dose-limiting toxicities or unexpected safety issues reported so far.
Presentation at Conference: Preliminary findings from the trial will be presented in a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting the early safety and efficacy of APR-1051.
Company Mission: Aprea Therapeutics aims to develop innovative cancer therapies that target cancer cells while minimizing harm to healthy cells, focusing on exploiting vulnerabilities in cancer cell mutations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APRE
Wall Street analysts forecast APRE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.770
Low
4.00
Averages
5.33
High
7.00
Current: 0.770
Low
4.00
Averages
5.33
High
7.00
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cancer Research Enters a New Phase with DDR Inhibitors
- Market Potential: In 2025, global sales of DNA Damage Response inhibitors (DDRi) exceeded $7 billion, with projections indicating that the oncology, diagnostics, and precision medicine markets will reach approximately $750 billion by 2030, highlighting rapid growth potential in this sector.
- Unique Technological Advantage: Onco-Innovations holds exclusive global rights to PNKP inhibitors, and its development of ONC010 nanoparticle encapsulation technology has shown significant biological rationale in treating various cancers, particularly solid tumors.
- Significant Preclinical Results: In mouse models, ONC010 extended median survival from 23 days to 60 days in PTEN-deficient colorectal cancer, demonstrating its efficacy in tumor growth inhibition and a favorable safety profile.
- Comprehensive IP Protection: Onco-Innovations' intellectual property portfolio covers core PNKP inhibitor molecules, nanoparticle delivery science, and synthetic lethality applications, creating a strong competitive moat that secures its leading position in the emerging market.
See More
Aprea Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Aprea Therapeutics reported a Q1 GAAP EPS of -$0.22, beating expectations by $0.01, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Position: As of March 31, 2026, the company reported cash and cash equivalents of $46.5 million, a significant increase from $14.6 million as of December 31, 2025, reflecting substantial progress in cash management.
- Operating Expense Assurance: Aprea believes that its cash reserves as of March 31, 2026, will be sufficient to meet projected operating and capital expenditure requirements into Q1 2028, providing a safety net for ongoing operations and reducing financial risk.
- Market Reaction Expectations: Following the earnings release, market interest in Aprea may increase, with investors closely monitoring its future financial performance and strategic direction to assess long-term investment value.
See More
Aprea Therapeutics Closes $30 Million Oversubscribed Financing
- Successful Financing: Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds allocated for general corporate purposes and R&D expenses, thereby enhancing financial flexibility to support its clinical projects.
- Clinical Trial Progress: The company's lead candidate APR-1051 is undergoing a Phase 1 trial for advanced solid tumors, showing promising clinical activity, with further updates expected in Q2 2026, which could drive stock price appreciation.
- Analyst Rating Maintained: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating for Aprea with a 12-month price target of $7, reflecting market confidence in its product potential and likely attracting more investor interest.
- Cash Flow Status: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, and with the recent financing, projected a cash runway through Q1 2027, providing a safeguard for the company's future development.
See More
Aprea Therapeutics Closes $30 Million Financing
- Significant Financing: Aprea Therapeutics has successfully closed an oversubscribed private placement financing, raising approximately $30 million, which will provide robust funding for the company's research and operational needs, expected to accelerate the development of targeted therapies for biomarker-defined cancers.
- Investor Confidence: The financing was led by top-tier biotech investor Soleus Capital, with participation from new investors such as Vestal Point Capital and Squadron Capital Management, reflecting strong market confidence in the potential of APR-1051 to impact cancer treatment.
- Clinical Trial Expansion: Aprea plans to enroll at least 50 patients with uterine serous carcinoma and platinum-resistant ovarian cancer to evaluate the efficacy of APR-1051, a strategy that will help clarify the clinical development path and accelerate insight generation in biomarker-defined patient populations.
- Future Development Outlook: The company intends to exercise the newly issued warrants before 2029, further strengthening its capital structure to support innovation and competitiveness in the cancer treatment market.
See More
Wedbush Reiterates Outperform Rating for Aprea Therapeutics
- Successful Financing: Aprea Therapeutics announced the completion of an oversubscribed private placement financing totaling approximately $30 million, which will provide crucial funding for its clinical trials and product development, enhancing the company's competitiveness in the biopharmaceutical sector.
- Clinical Trial Progress: The company's lead product candidate, APR-1051, is undergoing a Phase 1 clinical trial for patients with advanced solid tumors harboring cancer-associated genetic alterations, with preliminary data showing positive clinical activity, laying the groundwork for future market introduction.
- Dose Escalation Study: The dose-escalation study for APR-1051 is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026, which will include patients with uterine serous carcinoma, colorectal cancer, and HPV+ tumors, demonstrating the company's continued commitment to clinical research.
- Market Performance: Aprea Therapeutics' stock has traded between $0.54 and $2.30 over the past year, currently priced at $0.78, reflecting a 5.98% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Aprea Therapeutics Secures $30 Million Financing for APR-1051 Development
- Clinical Trial Progress: Aprea Therapeutics reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during its ongoing Phase 1 ACESOT-1051 trial, with a 50% reduction in tumor size at the first imaging assessment and an additional 9.5% reduction at the second assessment, indicating the drug's potential efficacy.
- Enrollment Expansion Plans: The company plans to enroll at least 50 patients with uterine serous carcinoma and other high-need patient groups beyond the existing biomarker-enriched cohorts, addressing significant unmet medical needs, with dose escalation expected to complete by the second quarter of 2027.
- Financing Details: Aprea announced an oversubscribed $30 million private placement led by Soleus Capital, with proceeds intended for general corporate purposes and R&D activities, which is expected to extend the company's cash runway into the first quarter of 2028.
- Stock Performance: APRE shares have traded between $0.54 and $2.30 over the past year, closing at $0.68, down 2.43% on the last trading day, but showing an 8.35% increase in pre-market trading, reflecting positive market sentiment regarding its financing and clinical advancements.
See More
Cancer Research Enters a New Phase with DDR Inhibitors
- Market Potential: In 2025, global sales of DNA Damage Response inhibitors (DDRi) exceeded $7 billion, with projections indicating that the oncology, diagnostics, and precision medicine markets will reach approximately $750 billion by 2030, highlighting rapid growth potential in this sector.
- Unique Technological Advantage: Onco-Innovations holds exclusive global rights to PNKP inhibitors, and its development of ONC010 nanoparticle encapsulation technology has shown significant biological rationale in treating various cancers, particularly solid tumors.
- Significant Preclinical Results: In mouse models, ONC010 extended median survival from 23 days to 60 days in PTEN-deficient colorectal cancer, demonstrating its efficacy in tumor growth inhibition and a favorable safety profile.
- Comprehensive IP Protection: Onco-Innovations' intellectual property portfolio covers core PNKP inhibitor molecules, nanoparticle delivery science, and synthetic lethality applications, creating a strong competitive moat that secures its leading position in the emerging market.
See More
Aprea Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Aprea Therapeutics reported a Q1 GAAP EPS of -$0.22, beating expectations by $0.01, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Position: As of March 31, 2026, the company reported cash and cash equivalents of $46.5 million, a significant increase from $14.6 million as of December 31, 2025, reflecting substantial progress in cash management.
- Operating Expense Assurance: Aprea believes that its cash reserves as of March 31, 2026, will be sufficient to meet projected operating and capital expenditure requirements into Q1 2028, providing a safety net for ongoing operations and reducing financial risk.
- Market Reaction Expectations: Following the earnings release, market interest in Aprea may increase, with investors closely monitoring its future financial performance and strategic direction to assess long-term investment value.
See More
Aprea Therapeutics Closes $30 Million Oversubscribed Financing
- Successful Financing: Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds allocated for general corporate purposes and R&D expenses, thereby enhancing financial flexibility to support its clinical projects.
- Clinical Trial Progress: The company's lead candidate APR-1051 is undergoing a Phase 1 trial for advanced solid tumors, showing promising clinical activity, with further updates expected in Q2 2026, which could drive stock price appreciation.
- Analyst Rating Maintained: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating for Aprea with a 12-month price target of $7, reflecting market confidence in its product potential and likely attracting more investor interest.
- Cash Flow Status: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, and with the recent financing, projected a cash runway through Q1 2027, providing a safeguard for the company's future development.
See More
Aprea Therapeutics Closes $30 Million Financing
- Significant Financing: Aprea Therapeutics has successfully closed an oversubscribed private placement financing, raising approximately $30 million, which will provide robust funding for the company's research and operational needs, expected to accelerate the development of targeted therapies for biomarker-defined cancers.
- Investor Confidence: The financing was led by top-tier biotech investor Soleus Capital, with participation from new investors such as Vestal Point Capital and Squadron Capital Management, reflecting strong market confidence in the potential of APR-1051 to impact cancer treatment.
- Clinical Trial Expansion: Aprea plans to enroll at least 50 patients with uterine serous carcinoma and platinum-resistant ovarian cancer to evaluate the efficacy of APR-1051, a strategy that will help clarify the clinical development path and accelerate insight generation in biomarker-defined patient populations.
- Future Development Outlook: The company intends to exercise the newly issued warrants before 2029, further strengthening its capital structure to support innovation and competitiveness in the cancer treatment market.
See More
Wedbush Reiterates Outperform Rating for Aprea Therapeutics
- Successful Financing: Aprea Therapeutics announced the completion of an oversubscribed private placement financing totaling approximately $30 million, which will provide crucial funding for its clinical trials and product development, enhancing the company's competitiveness in the biopharmaceutical sector.
- Clinical Trial Progress: The company's lead product candidate, APR-1051, is undergoing a Phase 1 clinical trial for patients with advanced solid tumors harboring cancer-associated genetic alterations, with preliminary data showing positive clinical activity, laying the groundwork for future market introduction.
- Dose Escalation Study: The dose-escalation study for APR-1051 is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026, which will include patients with uterine serous carcinoma, colorectal cancer, and HPV+ tumors, demonstrating the company's continued commitment to clinical research.
- Market Performance: Aprea Therapeutics' stock has traded between $0.54 and $2.30 over the past year, currently priced at $0.78, reflecting a 5.98% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Aprea Therapeutics Secures $30 Million Financing for APR-1051 Development
- Clinical Trial Progress: Aprea Therapeutics reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during its ongoing Phase 1 ACESOT-1051 trial, with a 50% reduction in tumor size at the first imaging assessment and an additional 9.5% reduction at the second assessment, indicating the drug's potential efficacy.
- Enrollment Expansion Plans: The company plans to enroll at least 50 patients with uterine serous carcinoma and other high-need patient groups beyond the existing biomarker-enriched cohorts, addressing significant unmet medical needs, with dose escalation expected to complete by the second quarter of 2027.
- Financing Details: Aprea announced an oversubscribed $30 million private placement led by Soleus Capital, with proceeds intended for general corporate purposes and R&D activities, which is expected to extend the company's cash runway into the first quarter of 2028.
- Stock Performance: APRE shares have traded between $0.54 and $2.30 over the past year, closing at $0.68, down 2.43% on the last trading day, but showing an 8.35% increase in pre-market trading, reflecting positive market sentiment regarding its financing and clinical advancements.
See More
